Emmaus Life Sciences (OTCMKTS:EMMA) Releases Earnings Results

Emmaus Life Sciences (OTCMKTS:EMMA) issued its earnings results on Friday. The company reported ($0.03) EPS for the quarter, Zacks reports. The company had revenue of $3.38 million for the quarter.

Emmaus Life Sciences Price Performance

Shares of EMMA traded up $0.00 during mid-day trading on Friday, reaching $0.01. The company’s stock had a trading volume of 15,000 shares, compared to its average volume of 54,728. Emmaus Life Sciences has a 12-month low of $0.00 and a 12-month high of $0.05. The stock has a market cap of $823,871.40, a PE ratio of -0.13 and a beta of 7.41. The company’s 50 day moving average is $0.01 and its 200 day moving average is $0.01.

Emmaus Life Sciences Company Profile

Emmaus Life Sciences, Inc, a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.